ERBB2 and neoplasm: To further substantiate the promoting effect of CAR-modified macrophages on T-cell tumor infiltration, we established a B16-HER2 subcutaneous tumor model in immunocompetent C57BL/6 mice, and CAR-modified iBMDMs were administered intravenously one week after tumor inoculation.